Skip to content
Science for cure
Personalised cancer therapy

Providing hope for cancer patients: Our vision for a better future

Imagine a world where cancer patients who lack effective treatment options can be cured. With our innovative cell therapy product, currently in clinical trial, we are bringing this vision closer to reality. Our unique approach trains the patient’s own immune cells to target and eliminate cancer cells, providing a tailor-made treatment for each patient.

Meet our team and learn more about our mission

NEOGAP - The story

NEOGAP Therapeutics is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology.

Discover NEOGAP's innovative pTTL cell therapy and patented technology

Our pTTL cell therapy product, which targets neoantigens, is just one example of our novel technology at NEOGAP. Developed using our proprietary PIOR® and patented EpiTCer® technologies, pTTL generates T cells targeting neoantigens using immune cells from cancer patients as starting material.

Learn more about our innovative technologies

The growing colorectal cancer therapeutics market

NEOGAP is dedicated to advancing the field of personalised immunotherapy to combat cancer, starting with our focus on colorectal cancer. Our experienced team of professionals from academia and the pharmaceutical industry is committed to developing innovative solutions that are at the forefront of cancer research. Our pTTL cell therapy product is a testament to this dedication.

We also believe in the power of collaboration and are open to partnering with organisations that share our vision for advancing the field of personalised immunotherapy for cancer treatment.

Learn more

Latest news from NEOGAP

Stay in the loop on our latest developments by reading our news.

Click here for updates